Literature DB >> 3717162

Family studies of mephenytoin hydroxylation deficiency.

T Inaba, M Jurima, W Kalow.   

Abstract

A genetic polymorphism characterized by deficient drug oxidation exists for the hydroxylation of mephenytoin. This deficiency was first recognized in a family study that suggested an autosomal recessive pattern of inheritance. To confirm the observation, we investigated 28 relatives of five poor metabolizers. Subjects ingested 50 mg of mephenytoin, and the 24-hr urine was analyzed for hydroxymephenytoin. The pedigree data shown here provide strong evidence that deficient mephenytoin hydroxylation is an autosomal recessive trait.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3717162      PMCID: PMC1684828     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  11 in total

1.  Stereoselective metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man.

Authors:  A Küpfer; P V Desmond; S Schenker; R A Branch
Journal:  J Pharmacol Exp Ther       Date:  1982-06       Impact factor: 4.030

2.  Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians.

Authors:  T Inaba; M Jurima; M Nakano; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1984-11       Impact factor: 6.875

3.  Stereoselective metabolism of mephenytoin in man.

Authors:  A Küpfer; R K Roberts; S Schenker; R A Branch
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

4.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

5.  In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase.

Authors:  T Inaba; M Jurima; W A Mahon; W Kalow
Journal:  Drug Metab Dispos       Date:  1985 Jul-Aug       Impact factor: 3.922

6.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

7.  Mephenytoin hydroxylation deficiency: kinetics after repeated doses.

Authors:  A Küpfer; P Desmond; R Patwardhan; S Schenker; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1984-01       Impact factor: 6.875

8.  Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Authors:  A Küpfer; R Preisig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians.

Authors:  M Jurima; T Inaba; D Kadar; W Kalow
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

10.  Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.

Authors:  P J Wedlund; W S Aslanian; C B McAllister; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1984-12       Impact factor: 6.875

View more
  11 in total

1.  Human cytochrome P-450 PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10.

Authors:  R R Meehan; J R Gosden; D Rout; N D Hastie; T Friedberg; M Adesnik; R Buckland; V van Heyningen; J Fletcher; N K Spurr
Journal:  Am J Hum Genet       Date:  1988-01       Impact factor: 11.025

Review 2.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

3.  Novel mutations in the cytochrome P450 2C19 gene: a pitfall of the PCR-RFLP method for identifying a common mutation.

Authors:  Yumiko Ohkubo; Akihito Ueta; Naoki Ando; Tetsuya Ito; Sachiko Yamaguchi; Kantaro Mizuno; Satoshi Sumi; Tohru Maeda; Daiju Yamazaki; Yukihisa Kurono; Shinji Fujimoto; Hajime Togari
Journal:  J Hum Genet       Date:  2005-11-24       Impact factor: 3.172

4.  Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of lung cancer.

Authors:  Chikako Kiyohara; Taro Shirakawa; Julian M Hopkin
Journal:  Environ Health Prev Med       Date:  2002-05       Impact factor: 3.674

5.  The induction effect of rifampicin on activity of mephenytoin 4'-hydroxylase related to M1 mutation of CYP2C19 and gene dose.

Authors:  H J Feng; S L Huang; W Wang; H H Zhou
Journal:  Br J Clin Pharmacol       Date:  1998-01       Impact factor: 4.335

Review 6.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Mephenytoin hydroxylation in the Cuna Amerindians of Panama.

Authors:  T Inaba; L F Jorge; T D Arias
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

8.  In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase.

Authors:  D J Birkett; D Rees; T Andersson; F J Gonzalez; J O Miners; M E Veronese
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

9.  Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.

Authors:  A Drøhse; L Bathum; K Brøsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

10.  Chromosomal organization of the cytochrome P450-2C gene family in the mouse: a locus associated with constitutive aryl hydrocarbon hydroxylase.

Authors:  R R Meehan; R M Speed; J R Gosden; D Rout; J J Hutton; B A Taylor; J Hilkens; V Kroezen; J Hilgers; M Adesnik
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.